RRR schreef op 16 mei 2016 15:08:
[...]
The number of outstanding shares as of 13 April 2016 amounts to 483,436,615 and the current
authorised share capital amounts to 550,000,000 shares. The rationale behind the proposed
increase of the authorised capital from 550,000,000 shares to 650,000,000 shares is to create
sufficient shares to enable the Company (i) to take advantage of new opportunities for
acquisition of additional products, where such new products can be obtained on advantageous
terms and (ii) to invest in increasing its own commercialization capabilities to accelerate growth
in revenues. Such opportunities present themselves from time to time and the Company is
exploring a number of such potential positive moves. The remainder of the un-issued share
capital allows the Company to retain a share reserve, as is typical for companies operating in
high growth sectors such as biotechnology.
www.pharming.com/wp-content/uploads/2...inderdaad...lezen...
en niet zomaar wat suggereren.
(maar als ze echt worden uitgegeven heb ik het mis... maar dat kan ik nergens lezen... jij wel Wijsdom?